Catalyst Pharmaceuticals Inc. plans to offer and sell up to 11 million common shares in an underwritten public offering.
The company plans to grant underwriters an overallotment option to buy up to an additional 15% of the shares offered.
Net proceeds will be used to fund clinical studies of company's drug Firdapse and to fund its precommercialization activities, and for general corporate purposes.
Piper Jaffray & Co. is acting as the lead book runner. SunTrust Robinson Humphrey Inc. is also acting as a book runner.
